Saturday 17 October 2026 Export RGEN’s income statement to Excel — free account

Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%

Follow RGEN

Alert me

Market cap: $11.7B
P/E: 234×
Fwd P/E: 112×
Dividend yield: —
F-score: 6/9
Altman Z: 7.49
Beneish M: −2.52
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 15.26

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	1	—	—	—	1	—	1	1	1	3	1

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 11,690.00

Revenue 785.10

Net Income 41.54

Free Cash Flow 110.35

Net Debt (259.40)

Current Ratio 9.05

Debt/Equity 0.26

P/E ratio 233.60

Fwd P/E 112.00

P/S ratio 12.59

P/B ratio 4.68

Past 5Y EPS Growth (4.98%)

This Y EPS Growth 20.66%

Next Y EPS Growth 28.40%

Next Y revenue growth 12.02%

Next 5Y EPS Growth 26.50%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 84.61%

10-year low 10-year high

P/S against its own 10 years 46.92%

10-year low 10-year high

P/B against its own 10 years 45.78%

10-year low 10-year high

EV/Sales against its own 10 years 45.08%

10-year low 10-year high

EV/FCF against its own 10 years 64.58%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	751	757	768	810
Receivables	124	134	159	158
Inventory	202	143	170	187
Other	—	—	—	—
	1,111	1,066	1,137	1,201

	2023	2024	2025	Q'26
Payables	20	32	30	33
ST’ Debt	69	—	—	—
Other	13	17	5	3
	165	127	136	133

Compound Annual Growth %

	10y	5y	3y
Sales	24.35%	15.05%	(2.70%)
Cash Flow	22.80%	13.40%	(11.96%)
Earnings	18.00%	(3.99%)	(35.94%)
Book Value	32.88%	6.61%	3.30%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	194	204	—	—	—
’25	169	182	189	198	738
’24	153	159	155	168	634
’23	165	159	141	167	632
’22	206	208	201	187	802
’21	143	163	178	187	671
’20	76	87	94	109	366

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	28	33	—	—	—
’25	15	29	48	26	117
’24	45	42	49	39	175
’23	11	34	39	29	114
’22	23	46	41	62	172
’21	9	38	22	50	119
’20	10	17	21	15	63

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	23	27	—	—	—
’25	11	21	43	18	92
’24	36	35	43	28	142
’23	2	25	30	18	75
’22	(5)	20	(16)	40	39
’21	0	20	11	16	48
’20	4	12	16	3	36

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.15	0.09	—	—	—
’25	0.10	0.26	0.26	0.23	0.86
’24	0.06	0.10	(0.01)	(0.60)	(0.46)
’23	0.27	0.35	0.32	(0.28)	0.74
’22	0.81	0.88	0.71	0.85	3.24
’21	0.52	0.64	0.58	0.50	2.24
’20	0.18	0.30	0.27	0.36	1.11

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	20.07	28.48	29.56	49.07	78.41	162.29	137.21	110.45	113.50	102.97	Analyst estimates 2026–2028 Powerpack
	High	34.06	46.81	70.50	99.25	212.55	327.32	265.78	200.98	211.13	182.52
People
People	Employees	236	476	548	761	1,128	1,852	2,025	1,783	1,778	2,000
	Revenue/emp, $m	0.44	0.30	0.35	0.36	0.32	0.36	0.40	0.35	0.36	0.37
Income, $m
Income, $m	Revenue	105	141	194	270	366	671	802	632	634	738
	Gross margin, %	54.93	52.53	55.40	55.93	57.23	58.35	56.85	44.03	43.29	52.32
	EBT	12	7	21	26	59	154	219	57	(27)	62
	EBT margin, %	11.18	5.13	11.05	9.68	16.17	22.90	27.34	8.97	(4.26)	8.45
	Net income	12	28	17	21	60	128	186	36	(26)	49
	Depreciation	5	11	20	28	38	50	53	71	85	95
Per share, $
Per share, $	Revenue	3.11	3.69	4.43	5.59	6.97	12.19	14.45	11.35	11.34	13.13
	Earnings	0.35	0.74	0.38	0.44	1.14	2.33	3.35	0.75	(0.46)	0.87
	Cash flow	0.22	0.46	0.75	1.39	1.19	2.16	3.10	2.04	3.14	2.09
	Capex	(0.13)	(0.14)	(0.32)	(0.48)	(0.50)	(1.30)	(2.40)	(0.70)	(0.59)	(0.45)
	Free cash flow	0.10	0.31	0.43	0.91	0.69	0.87	0.70	1.34	2.55	1.63
	Book value	5.03	15.47	14.06	21.92	29.10	31.81	34.45	35.26	35.27	37.45
	Shares, m	34	38	44	48	53	55	55	56	56	56
Valuation, ×
Valuation, ×	P/E	89.00	50.77	138.79	205.56	168.10	113.18	48.21	267.52	0.00	188.34
	P/S	10.00	10.03	11.90	16.55	27.50	21.73	11.21	15.80	12.69	12.48
	P/B	6.20	2.40	3.75	4.22	6.59	8.33	4.70	5.08	4.08	4.38
	EV/Sales	9.56	10.20	11.95	15.43	26.27	21.36	10.95	15.53	12.44	12.27
	EV/FCF	308.33	120.09	115.98	94.66	265.25	300.03	104.81	131.03	81.98	212.32
Cash, $m
Cash, $m	Operating cash flow	8	17	33	67	63	119	172	114	175	117
	Capex	(4)	(5)	(14)	(23)	(26)	(71)	(133)	(39)	(33)	(25)
	Free cash flow	3	12	19	44	36	48	39	75	142	92
Balance, $m
Balance, $m	Working capital	163	218	146	594	583	556	594	946	939	1,002
	Total debt	95	99	103	237	270	357	416	580	526	542
	Net debt	(47)	(75)	(90)	(301)	(448)	(247)	(208)	(172)	(232)	(225)
	Shareholders’ equity	169	592	616	1,060	1,529	1,750	1,911	1,965	1,973	2,106
Returns, %
Returns, %	ROA	5.37	5.49	2.19	1.97	3.63	6.02	7.61	1.33	(0.90)	1.69
	ROIC	8.17	1.69	3.09	2.97	4.03	6.95	8.25	1.66	(1.26)	1.83
	ROE	8.01	7.46	2.75	2.56	4.63	7.82	10.16	1.84	(1.30)	2.40

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SOLV Solventum Corporation	$15.0B	10.4×	39.0×	+2.22% (above 0%: growing)	+1.92% (above 0%: growing)	+144.07% (above 0%: growing)	58.22%	8.19%	Compare
BAX Baxter International Inc.	$13.3B	— (loss-making)	44.7×	+5.34% (above 0%: growing)	+33.33% (above 0%: growing)	+119.48% (above 0%: growing)	34.86%	7.33%	Compare
RGEN Repligen Corporation	$11.7B	234×	112×	+11.93% (above 0%: growing)	−65.38% (below 0%: shrinking)	+27.10% (above 0%: growing)	53.91%	6.85%
COO The Cooper Companies, Inc.	$10.9B	19.8×	28.7×	+0.56% (above 0%: growing)	+357.14% (above 0%: growing)	+65.96% (above 0%: growing)	66.77%	20.82%	Compare
AVTR Avantor, Inc.	$10.9B	— (loss-making)	25.5×	+0.53% (above 0%: growing)	−33.33% (below 0%: shrinking)	+12.66% (above 0%: growing)	31.73%	7.20%	Compare
ALGN Align Technology, Inc.	$10.6B	25.6×	20.7×	+4.32% (above 0%: growing)	−12.21% (below 0%: shrinking)	+85.77% (above 0%: growing)	71.71%	14.58%	Compare
ATR AptarGroup, Inc.	$7.9B	22.2×	21.0×	+6.26% (above 0%: growing)	−18.34% (below 0%: shrinking)	−23.07% (below 0%: shrinking)	35.61%	12.34%	Compare
BLCO Bausch + Lomb Corporation	$6.0B	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+251.85% (above 0%: growing)	62.20%	5.95%	Compare
TFX Teleflex Incorporated	$5.4B	— (loss-making)	45.3×	+28.88% (above 0%: growing)	−17.33% (below 0%: shrinking)	+220.14% (above 0%: growing)	58.16%	12.77%	Compare
Median of peers	$10.7B	21.0×	28.7×	+4.83%	−12.21%	+102.63%	58.19%	10.26%

All 55 Medical Instruments & Supplies stocks →

Repligen Corporation (RGEN) key facts

Strength: Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024.
Repligen Corporation (RGEN) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, RGEN traded at $175.20, a market capitalization of $11.7 billion.
Return on equity was 2.40% and debt-to-equity 0.26.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.49 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.